Janus Kinase 2 Polymorphisms Are Associated with Risk in Patients with Gastric Cancer in a Chinese Population

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Yang, Li ^a   Liu, Dongxiao ^b   Liang, Song ^a   Guo, Renhua ^a   Zhang, Zhihong ^a   Xu, Hao ^a   Yang, Chao ^a   Zhu, Yi ^a,c  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b Nanjing Second Hospital   (China)

^c Jiangsu Province Academy of Clinical Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ADULT; AGED; ARTICLE; CANCER RISK; CHINESE; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; JANUS KINASE 2 GENE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; RISK FACTOR; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; ASIAN CONTINENTAL ANCESTRY GROUP; CANCER STAGING; CASE CONTROL STUDY; CHINA; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MIDDLE AGED; PATHOLOGY; RISK; STOMACH TUMOR;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; STOMACH NEOPLASMS;

EID: 84878157556     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064628     Document Type: Article

References (32)

1. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M, (2005) Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 366: 1784-1793.
2. Pisani P, Parkin DM, Bray F, Ferlay J, (1999) Erratum: Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer, 83, 18-29 (1999). Int J Cancer 83: 870-873.
3. Correa P, (1992) Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 52: 6735-6740.
4. Wu MS, Chen CJ, Lin JT, (2005) Host-environment interactions: their impact on progression from gastric inflammation to carcinogenesis and on development of new approaches to prevent and treat gastric cancer. Cancer Epidemiol Biomarkers Prev 14: 1878-1882.
5. Yang L, Gu HJ, Zhu HJ, Sun QM, Cong RH, et al. (2008) Tissue inhibitor of metalloproteinase-2 G-418C polymorphism is associated with an increased risk of gastric cancer in a Chinese population. Eur J Surg Oncol 34: 636-641.
6. Gu H, Yang L, Tang N, Zhou B, Zhu H, et al. (2008) Association of endothelin-converting enzyme-1b C-338A polymorphism with gastric cancer risk: a case-control study. Eur J Cancer 44: 1253-1258.
7. Gu H, Yang L, Sun Q, Zhou B, Tang N, et al. (2008) Gly82Ser polymorphism of the receptor for advanced glycation end products is associated with an increased risk of gastric cancer in a Chinese population. Clin Cancer Res 14: 3627-3632.
8. Zhu H, Yang L, Zhou B, Yu R, Tang N, et al. (2006) Myeloperoxidase G-463A polymorphism and the risk of gastric cancer: a case-control study. Carcinogenesis 27: 2491-2496.
9. Constantinescu SN, Girardot M, Pecquet C, (2008) Mining for JAK-STAT mutations in cancer. Trends Biochem Sci 33: 122-131.
10. Teng CB, Diao HL, Ma XH, Xu LB, Yang ZM, (2004) Differential expression and activation of Stat3 during mouse embryo implantation and decidualization. Mol Reprod Dev 69: 1-10.
11. Chan KS, Carbajal S, Kiguchi K, Clifford J, Sano S, et al. (2004) Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis. Cancer Res 64: 2382-2389.
12. Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, et al. (2003) Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 63: 2948-2956.
13. Zhou J, Xie Y, Zhao Y, Wang S, Li Y, (2011) Human gastrin mRNA expression up-regulated by Helicobacter pylori CagA through MEK/ERK and JAK2-signaling pathways in gastric cancer cells. Gastric Cancer 14: 322-331.
14. Traer E, Mackenzie R, Snead J, Agarwal A, Eiring AM, et al. (2011) Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia 26: 1140-1143.
15. Lakshmanan I, Ponnusamy MP, Das S, Chakraborty S, Haridas D, et al. (2011) MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene 31: 805-817.
16. Yoon YK, Kim HP, Han SW, Oh do Y, Im SA, et al. (2010) KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. Mol Carcinog 49: 353-362.
17. Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ, et al. (2009) Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res 69: 193-202.
18. Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, et al. (2009) Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer 100: 134-144.
19. Ferrand A, Kowalski-Chauvel A, Bertrand C, Pradayrol L, Fourmy D, et al. (2004) Involvement of JAK2 upstream of the PI 3-kinase in cell-cell adhesion regulation by gastrin. Exp Cell Res 301: 128-138.
20. Ding L, Xu Y, Zhang W, Deng Y, Si M, et al. (2010) MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res 20: 784-793.
21. Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A, (2008) Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 111: 2785-2789.
22. Prager M, Buttner J, Haas V, Baumgart DC, Sturm A, et al. (2011) The JAK2 variant rs10758669 in Crohn's disease: altering the intestinal barrier as one mechanism of action. Int J Colorectal Dis 27: 565-573.
23. Ferguson LR, Han DY, Fraser AG, Huebner C, Lam WJ, et al. (2010) Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population. Mutat Res 690: 108-115.
24. Cong Y, Guo X, Liu X, Cao D, Jia X, et al. (2009) Association of the single nucleotide polymorphisms in the extracellular matrix metalloprotease-9 gene with PACG in southern China. Mol Vis 15: 1412-1417.
25. Vera J, Rateitschak K, Lange F, Kossow C, Wolkenhauer O, et al. (2011) Systems biology of JAK-STAT signalling in human malignancies. Prog Biophys Mol Biol 106: 426-434.
26. Santos FP, Verstovsek S, (2011) JAK2 inhibitors: what's the true therapeutic potential? Blood Rev 25: 53-63.
27. Yu H, Pardoll D, Jove R, (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798-809.
28. Pham TM, Fujino Y, Ide R, Kubo T, Shirane K, et al. (2006) Prospective study of vegetable consumption and liver cancer in Japan. Int J Cancer 119: 2408-2411.
29. Zhong Y, Wu J, Ma R, Cao H, Wang Z, et al. (2011) Association of Janus kinase 2 (JAK2) polymorphisms with acute leukemia susceptibility. Int J Lab Hematol 34: 248-253.
30. Lee JJ, Wu X, Hildebrandt MA, Yang H, Khuri FR, et al. (2011) Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) 4: 185-193.
31. Kelley JR, Duggan JM, (2003) Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56: 1-9.
32. Parkin DM, (2004) International variation. Oncogene 23: 6329-6340.